Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and ...

EDT Gossamer Bio (GOSS) reports Q4 revenue $9.4M, consensus $7.0MLight Up your Portfolio with Spark:Easily identify stocks' risks and ...

Cash, cash equivalents and marketable securities as of December 31, 2024, were $294.5 million. As a result, we expect our ...

The Kern County Coroner’s Office has identified a man killed after a crash on Gossamer Grove Boulevard as 22-year-old Luis ...

SAN DIEGO (AP) — SAN DIEGO (AP) — Gossamer Bio Inc. (GOSS) on Thursday reported a loss of $33 million in its fourth quarter. On a per-share basis, the San Diego-based company said it had a loss of 15 ...

Gossamer Bio (GOSS) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.21 per share a year ago. These figures are ...

Gossamer Bio (NASDAQ:GOSS – Get Free Report) will likely be posting its quarterly earnings results before the market opens on ...

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and ...

Gossamer Bio develops Seralutinib, which is basically an inhaled TKI that targets vascular remodeling, inflammation, and fibrosis. This makes it ideal for treating PAH and PH-ILD. GOSS has so far ...

SAN DIEGO - Gossamer Bio, Inc. (NASDAQ: GOSS) saw its shares climb 5.4% after the biopharmaceutical company reported better-than-expected fourth quarter results and provided updates on its pulmonary ...

Newsroom is open 24 hours, please reach us by email at [email protected] or by phone Monday through Friday 9-5. You can place DBA (Fictitious Business Name Statement) orders online by clicking on t ...

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial ...